The analysts covering Editas Medicine, Inc. (NASDAQ:EDIT) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Revenue estimates were cut sharply as analysts signalled a weaker outlook - perhaps a sign that investors should temper their expectations as well.

Following the latest downgrade, the current consensus, from the eleven analysts covering Editas Medicine, is for revenues of US$14m in 2026, which would reflect a sizeable 63% reduction in Editas Medicine's sales over the past 12 months. The loss per share is expected to ameliorate slightly, reducing to US$1.01. Yet before this consensus update, the analysts had been forecasting revenues of US$23m and losses of US$1.01 per share in 2026. So there's definitely been a change in sentiment in this update, with the analysts administering a substantial haircut to this year's revenue estimates, while at the same time holding losses per share steady.

Of course, another way to look at these forecasts is to place them into context against the industry itself. One more thing stood out to us about these estimates, and it's the idea that Editas Medicine's decline is expected to accelerate, with revenues forecast to fall at an annualised rate of 74% to the end of 2026. This tops off a historical decline of 1.5% a year over the past five years. Compare this against analyst estimates for companies in the broader industry, which suggest that revenues (in aggregate) are expected to grow 22% annually. So it's pretty clear that, while it does have declining revenues, the analysts also expect Editas Medicine to suffer worse than the wider industry.

The Bottom Line

Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on Editas Medicine after today.

As you can see, the analysts clearly aren't bullish, and there might be good reason for that. We've identified some potential issues with Editas Medicine's financials, such as dilutive stock issuance over the past year. Learn more, and discover the 4 other risks we've identified, for free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.